Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Triple-Negative Breast Cancer (TNBC)
Phase PHASE3
Enrollment 416
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, randomized, double-blind study aims to assess the safety and efficacy of AK112 in combination with Nab-Paclitaxel, compared to a placebo plus Nab-Paclitaxel, as a first-line treatment for inoperable locally advanced or metastatic triple-negative breast cancer (TNBC).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: AK112 — AK112 via intravenous (IV) infusion
  • Drug: Nab-paclitaxel — Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
  • Drug: Placebo — Placebo via IV infusion

Primary Outcomes

  • PFS assessed by IRRC (Up to approximately 2 years)
  • OS (Up to approximately 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-02-07
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Akeso
Contact Information
Study Contact:
Xufang Yu
+86(0760)89873999
clinicaltrials@akesobio.com
Binghe Xu
010-87788993
xubinghe@medmail.com.cn
Cancer Hospital Chinese Academy of Medical Sciences
Interventions
  • Drug: AK112 — AK112 via intravenous (IV) infusion
  • Drug: Nab-paclitaxel — Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
  • Drug: Placebo — Placebo via IV infusion
Study Locations (1 sites)
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign a written informed consent form. 2. Age at enrollment is ≥ 18 and ≤ 75 years, both males and females are eligible. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy of ≥ 3 months. 5. Histologically confirmed unresectable locally advanced or metastatic breast cancer with negative status for ER, PR, and HER-2. 6. Subjects who have not received prior systemic treatment for advanced breast cancer are eligible for the study. 7. Suitable for monotherapy with taxane-based agents. 8. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 9. Adequate organ function. Exclusion Criteria: 1. Patients with locally recurrent disease who are eligible for surgery or radiotherapy. 2. History of other malignancies within the past 5 years. 3. Active autoimmune disease requiring systemic treatment within the past 2 years. 4. Pregnant or breastfeeding women. 5. Concurrent participation in another clinical trial, unless it is an observational or non-interventional study or in the follow-up phase of an interventional study. 6. Participants with clinically symptomatic pleural effusion, pericardial effusion, or ascites that require repeated drainage. 7. Participants with a history of immune deficiency; those who test positive for HIV antibodies; those currently using systemic corticosteroids or other immunosuppressive agents on a long-term basis. 8. Individuals with known active tuberculosis (TB), or those suspected of having active TB (who must undergo clinical evaluation for exclusion), and those with known active syphilis infection.
Conditions Preeclampsia
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Prolongation of at least one week of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes (Up to 40 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-01-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Contact Information
Study Contact:
Catalina de Paco Matallana, MD
968369500
katy.depaco@gmail.com
Catalina de Paco Matallana, MD
968369500
katy.depaco@gmail.com
HCUVA
Interventions
N/A
Study Locations (1 sites)
HCUVA, El Palmar, Murcia 30120 Spain
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years * Women with singleton and twin pregnancies complicated by hypertensive states of pregnancy. Exclusion Criteria: * Minors under 18 years of age. * Women with mental disabilities. * Major congenital fetal anomaly.
Conditions Common Mental Health Problems, Anxiety, ...
Phase NA
Enrollment 660
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to understand how to deliver online group therapy for adults with common mental health problems in a personalised way. This study will test a new online group therapy program for various common mental health problems like anxiety and depression. The therapy is based on an approach called the Unified Protocol, which includes eight modules teaching different coping skills. The therapy will be delivered via a video call and a website, which will also have helpful videos and information about coping skills. Aims: 1. Does changing the order of the therapy modules affect how well treatment works or how many patients drop-out of treatment? 2. Do some modules work better for different patients based on their individual features and if patients receive the therapy module that is most likely to be helpful for them first, does it mean they have a better chance of feeling better by the end of treatment? 3. Does online group therapy work as well to treat common mental health problems as standard care (individual cognitive behavioural therapy \[CBT\])? Hypotheses: 1. Changing the order of therapy modules will not change how well therapy works or how many people drop-out. 2. Patients with specific profiles (based on their individual characteristics) will benefit more from some treatment modules and will see greater improvements in their symptoms if they received their best therapy module before other modules 3. There will be no differences in overall treatment outcome or dropout rates when comparing online group therapy vs. individual CBT Researchers will compare whether delivering the modules in different orders, with five different versions of the treatment, to see if changing the order of therapy modules affects how well it works or drop-out rates. Researchers will test how best to match patients to the most helpful parts of treatment for them. The group therapy outcomes and costs will also be compared to data from patients who have had individual CBT to see how the intervention compares to standard care. Participants will: * Complete online symptom questionnaires before treatment starts and before each therapy session * Attend 12 weekly group therapy sessions delivered by a video call on a website (called Uplift-X). * Access online resources like videos and practice exercises to use between therapy sessions. * Complete the online symptom questionnaires again at the end of treatment and 6 months later.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Unified Protocol — The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.

Primary Outcomes

  • Post-treatment Negative Affectivity (NA) scale (Through study completion, an average of 11 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-30
Completion: 2026-09-30
Eligibility
Age: 17 Years and older
Sex: ALL
Volunteers: false
Enrollment: 660 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rotherham Doncaster and South Humber NHS Foundation Trust
Collaborators: Innovate UK, University of Sheffield, MindLife UK Ltd
Principal Investigators:
  • Jaime Delgadillo, PhD (PRINCIPAL_INVESTIGATOR) - University of Sheffield
Contact Information
Study Contact:
Melanie Simmonds-Buckley, PhD
+443000 212 456
melanie.simmonds-buckley@nhs.net
Jeannie McKie, PGDiP
+443000 212 456
j.mckie@nhs.net
Jodie Keyworth
07725833609
Jodie.keyworth@nhs.net
Rotherham Doncaster and South Humber NHS Foundation Trust
Interventions
  • Behavioral: Unified Protocol — The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.
Study Locations (2 sites)
Rotherham Doncaster and South Humber NHS Foundation Trust, Doncaster, South Yorkshire DN4 8QN United Kingdom
Devon Partnership NHS Trust, Exeter, EX2 5AF United Kingdom
Eligibility Criteria
Inclusion Criteria: * 17 years old and over * Literate and fluent in the English language, which would enable group interactions and learning via online materials * With access to an internet-connected device (e.g., computer, phone) and confidential space * Referred to NHS-TT services * Assessed by a qualified psychological professional and deemed to be eligible for high intensity CBT (this includes low risk of harm to self or others) * Currently on waiting list for high intensity CBT and not accessing any other psychological interventions. This includes patients accessing pharmacotherapy but who are additionally seeking psychological treatment * Presenting symptoms of one or more internalizing disorders (major depressive disorder, generalised anxiety disorder, panic disorder, agoraphobia, specific phobias, somatoform disorder, obsessive-compulsive and related disorders, body dysmorphic disorder, post-traumatic stress and related disorders) Exclusion Criteria: * 16 years old and under * Not able to speak or read English fluently, which would require more individualised support with interpreters * No access to internet-connected device or confidential space to engage with digital intervention * Not involved with NHS-TT services * Assessed by a qualified psychological professional and not deemed to be eligible for high intensity CBT on the basis of mental health condition and/or risk assessment (e.g., acute risk of suicide at the time of assessment) * Already accessing a high intensity psychotherapy or other forms of psychological treatment (e.g., private therapy, counselling) * Presenting with symptoms of eating disorders, substance use disorders, psychotic disorders, personality disorders, bipolar disorders identified at the time of initial assessment.
Conditions Breast Carcinoma, Breast Cancer Stage I,...
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women diagnosed with early-stage breast cancer need to make a decision about the therapeutic treatment to undertake. Since multiple factors can influence this decision, it is necessary to develop a decision-making support tool to assist them in making this choice. Main Objective: To develop a decision-making support tool for determining the treatment to undertake for women diagnosed with early-stage breast cancer and test its effectiveness on an experimental group.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Healthcare professionals — healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews
  • Other: Patients PDA group — Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires
  • Other: Patients control group — Participants will receive only the online link with the battery of questionnaires

Primary Outcomes

  • Development of an ad hoc Patient Decision Aid (PDA) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-22
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Gabriella Pravettoni (PRINCIPAL_INVESTIGATOR) - European Institute of Oncology
Contact Information
Study Contact:
Gabriella Pravettoni
0039 02 57489731
gabriella.pravettoni@ieo.it
Interventions
  • Other: Healthcare professionals — healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews
  • Other: Patients PDA group — Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires
  • Other: Patients control group — Participants will receive only the online link with the battery of questionnaires
Study Locations (1 sites)
European Institute of Oncology, Milan, Italy 20141 Italy
Eligibility Criteria
Inclusion Criteria: * be 18 or older; * have received/receive diagnosis of resectable breast cancer in the early stage; * women treated or who will undergo oncological treatment for early breast cancer; * demonstrate the absence of psychopathological features. * be willing and able to provide written informed consent/assent for the trial Exclusion Criteria: * breast cancer patients who showed physical or psychological issues, as well as cognitive impairments that prohibited their participation in this type of study; * neurological or psychiatric disorders that may compromise the patients' ability to take part in the study. * Distant metastases from breast cancer or locally advanced/unresectable disease * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Conditions Diabetes Mellitus Type 2 (T2DM)
Phase Not Applicable
Enrollment 162
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes mellitus being metabolic disorder, chronic in nature, is characterized by high levels of glucose in our blood, which often lead to organ dysfunction. Approximately 10.5 % of adult (20-79 years) have diabetes according to international Diabetes federation. Cardiorespiratory fitness (CRF) is the capability of our cardiopulmonary system to make oxygen available to our skeletal muscles during physical activities for prolonged time, and is known to be decreased with diabetes. Hemodynamic parameters are correlated with various cardiovascular disorders but little evidence of hemodynamic changes in diabetes patients is present and more studies must be done. This study aims to establish the link between hemodynamic changes and cardiopulmonary fitness in T2DM patients, which could inform clinical practices and interventions to improve management, reduce cardiovascular risks, and enhance the quality of life for these patients.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Exercise tolerance test — • The ETT will be performed using Bruce protocol. The Bruce protocol is a standardized treadmill exercise test used in Exercise Tolerance Testing (ETT) to evaluate cardiovascular fitness and diagnose heart conditions. This protocol is divided into seven stages, each stage duration is 3 minutes and date will be recorded at the end of the each stage. The recorded data will include heart Rate, Rate pressure product (∆RPP), HRR1 and Blood Pressure. STEP 1: Patient Preparation STEP 2: Consent and history: STEP 3: Start of ETT: • Graded Exercise STEP 4: Parameters Recorded During ETT: * Heart Rate: Monitoring heart rate response to exercise stress. * Exercise induced changes in heart rate (∆HR) along with change in rate pressure product (∆RPP) due to excercise intensity. STEP 5: Cardiopulmonary Fitness Assessment VO2 Max

Primary Outcomes

  • hemodynamic changes (Immediately after performing test)
  • Cardiorespiratory fitness (immediately after performing test)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2025-04-15
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bahria University
Contact Information
Study Contact:
Tahniat Ali
+923327503308
tahniyatali_999@yahoo.com
Tahniat Ali
03327503308
bahria university Health sciences campus karachi
Interventions
  • Other: Exercise tolerance test — • The ETT will be performed using Bruce protocol. The Bruce protocol is a standardized treadmill exercise test used in Exercise Tolerance Testing (ETT) to evaluate cardiovascular fitness and diagnose heart conditions. This protocol is divided into seven stages, each stage duration is 3 minutes and date will be recorded at the end of the each stage. The recorded data will include heart Rate, Rate pressure product (∆RPP), HRR1 and Blood Pressure. STEP 1: Patient Preparation STEP 2: Consent and history: STEP 3: Start of ETT: • Graded Exercise STEP 4: Parameters Recorded During ETT: * Heart Rate: Monitoring heart rate response to exercise stress. * Exercise induced changes in heart rate (∆HR) along with change in rate pressure product (∆RPP) due to excercise intensity. STEP 5: Cardiopulmonary Fitness Assessment VO2 Max
Study Locations (1 sites)
bahria university Health sciences campus karachi, Karachi, Sindh 75300 Pakistan
Eligibility Criteria
Inclusion Criteria: * Subjects who agreed to sign the informed consent form. * Subject with an age group 30-50yrs. * Female and male. * Controlled type 2 Diabetes Mellitus patients. Exclusion Criteria: * Patient performing any exercise. * cardiovascular diseases. * Patients with Cerebrovascular diseases. * Patients with Peripheral artery diseases. * Patients with pulmonary dysfunction.
Conditions Prediabetes, Lipid Profile, Hypertension...
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to is to determine the effects of baked potato with the skin (BP) + nutrition education focused on adherence for a Mediterranean Dietary Pattern (MEDNE) on glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds. The main questions it aims to answer are: * Does BP+MEDNE contribute to improvements in indices of glycemic control, vascular function, blood lipids, inflammation/oxidative stress, and body composition? * Does BP+MEDNE contribute to improvements to overall dietary intake and quality? Researchers will compare BP+MEDNE to MEDNE alone to see if BP+MEDNE can improve glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds. Participants will: * Be asked to come to the study site initially for a Screening Study Visit to confirm eligibility. * Be asked to come the study site for a Pre-Baseline and Pre-12-Week Study Visit (one week prior to Baseline and 12-Week Study Visits) for placement of placement of a continuous glucose monitor and wearable devices to be removed at Baseline and 12-Week Study Visits. * Be asked to come to the study site for Baseline, 6- and 12-Week Study Visits for assessments of glycemic control and cardiometabolic health. * Be asked to complete 3-Day Food Records throughout the 12 week study period for assessment of dietary quality (5 total) * Receive pre-recorded MEDNE ( which can be accessed via computer device/ipad/smartphone) after Baseline and 6-Week Study Visits. * If randomized to the BP+MEDNE group, participants will receive pre-prepared baked potatoes with the skin for the 12-week study period (every 3 weeks) at Baseline and 6-Week Study Visits and asked to come to the study site for picking up the pre-prepared baked potatoes at weeks 3 and 9 of the study period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mediterranean Diet Nutrition Education — Participants randomized to receive the Mediterranean Diet Nutrition Education will receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits, which will be created by the PI and Co-I's of the study (who are comprised of Professors who are either Registered Dietitian credentialed or have experience with creating nutrition/physical activity programs), including an explanation of the principles and components of a Mediterranean dietary pattern and its benefits, guidance on recommended intake of various food groups, budget-friendly strategies for incorporation, supporting resources (educational materials and online tools), and techniques for overcoming barriers to following a Mediterranean dietary pattern. Additional educational materials will be provided to participants through computer or web-based sources.
  • Behavioral: Mediterranean Diet Nutrition Education with Baked White Potato — Participants randomized to receive the Mediterranean Diet Nutrition Education with Baked White Potatoes will similarly receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits (same as the Mediterranean Diet Nutrition Education group). They will also receive will 100 g roasted white russet potatoes with the skin and will be asked to consume the regimen as a part of their meals (breakfast, lunch, dinner) or as a snack throughout the day to contribute to a balanced meal plan. The baked white potato regimen will be pre-portioned (in 100g amounts), stored in the freezer and given in freezer-microwave safe containers. The baked white potato regimen is approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat . In order to increase participants' compliance, they will be informed of a variety of ways to consume the baked white potato regimen.

Primary Outcomes

  • Change in HemoglobinA1c (Baseline and 12-Week Study Visits: 12 weeks)
  • Change in Blood Glucose Levels (Baseline, 6- and 12-Week Study Visits: 12 weeks)
  • Change in Plasma Insulin Levels (Baseline, 6- and 12-Week Study Visits: 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-24
Completion: 2026-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nevada, Las Vegas
Collaborators: Alliance for Potato Research and Education
Principal Investigators:
  • Neda S Akhavan, PhD, RD (PRINCIPAL_INVESTIGATOR) - University of Nevada, Las Vegas
Contact Information
Study Contact:
Neda S Akhavan, PhD, RD
702-708-2580
neda.akhavan@UNLV.edu
Sara K Rosenkranz, PhD
702-895-0938
sara.rosenkranz@unlv.edu
Neda S Akhavan, PhD, RD
8505446420
neda.akhavan@UNLV.edu
Department of Kinesiology and Nutrition Sciences
Interventions
  • Behavioral: Mediterranean Diet Nutrition Education — Participants randomized to receive the Mediterranean Diet Nutrition Education will receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits, which will be created by the PI and Co-I's of the study (who are comprised of Professors who are either Registered Dietitian credentialed or have experience with creating nutrition/physical activity programs), including an explanation of the principles and components of a Mediterranean dietary pattern and its benefits, guidance on recommended intake of various food groups, budget-friendly strategies for incorporation, supporting resources (educational materials and online tools), and techniques for overcoming barriers to following a Mediterranean dietary pattern. Additional educational materials will be provided to participants through computer or web-based sources.
  • Behavioral: Mediterranean Diet Nutrition Education with Baked White Potato — Participants randomized to receive the Mediterranean Diet Nutrition Education with Baked White Potatoes will similarly receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits (same as the Mediterranean Diet Nutrition Education group). They will also receive will 100 g roasted white russet potatoes with the skin and will be asked to consume the regimen as a part of their meals (breakfast, lunch, dinner) or as a snack throughout the day to contribute to a balanced meal plan. The baked white potato regimen will be pre-portioned (in 100g amounts), stored in the freezer and given in freezer-microwave safe containers. The baked white potato regimen is approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat . In order to increase participants' compliance, they will be informed of a variety of ways to consume the baked white potato regimen.
Study Locations (2 sites)
Department of Kinesiology and Nutrition Sciences, Las Vegas, Nevada 89154 United States
University of Nevada Las Vegas, Las Vegas, Nevada 89154 United States
Eligibility Criteria
Inclusion Criteria: * Men and postmenopausal women within the Las Vegas/Henderson NV area * Ages 45-80 years * BMI between 25-40 kg/m2 * HbA1c between 5.7-6.4% * Individuals from different demographic backgrounds (i.e., American Indian or Alaska Native, Caucasians, Asian, Black or African-American, Native Hawaiian, Hispanic, Latino or Pacific Islander) * Individuals who are considered "non-frequent" white potato consumers (\<2 servings of baked potatoes/week) * Individuals from all races, genders, sexual identities, and religions will be included * Individuals must follow certain guidelines, including avoiding new medications during the study or significant changes to lifestyle factors (e.g. beginning to smoke or exercise more or less than usual) Exclusion Criteria: * Individuals with uncontrolled hypertension (≥160/100mmHg), active cancer, asthma, thyroid, kidney, liver, or pancreatic diseases * Individuals who are currently using insulin, on dialysis, changing/adding hypoglycemic, anti-hypertensive, and hypocholesterolemic medication within ≤3 months (or throughout the study) * Individuals participating in weight loss programs or another clinical trial * Individuals who start smoking * Individuals who have unstable metabolic or chronic diseases * Individuals who may have allergies to potatoes * Woman who are currently pregnant, think they may be pregnant, or who is nursing cannot participate (women must be postmenopausal)
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Mental health issues are very common during and after pregnancy, and studies from around the world indicate that 10-15% of all pregnant and postpartum women experience depression. Risk factors for developing depression include a history of depression, low levels of social support, and stressful life events. The symptoms are the same as for depression during other periods of life, but often include feelings of inadequacy regarding motherhood, along with associated feelings of shame or guilt. Obsessive thoughts directed toward the baby may also be part of the symptomatology. Such thoughts are typically experienced as frightening by the mother but, in the vast majority of cases, do not pose any risk to the child. Maternal depression can also affect a mother's ability to bond with her baby, and difficulties in forming an attachment can, in turn, increase and perpetuate depressive symptoms. In the long term, insecure attachment between mother and child can lead to behavioral problems in the child, such as aggression and avoidance, anxiety and depression in adolescence, negative effects on cognitive development, and trust issues in close relationships. Baby swimming is a structured form of interaction that takes place in 34-degree Celsius water in a calm environment, aiming to teach the baby vital skills while stimulating social, intellectual, and motor development. At least one parent actively participates and is encouraged to perform various exercises. These activities strengthen the bond between the baby and the parent and contribute to making time in the water a safe and enjoyable experience. Previous studies have shown that baby swimming can improve attachment between parent and child. In the present project, the aim is to investigate whether baby swimming can be used as an intervention for depressive symptoms in new mothers and whether this intervention can reduce depressive symptoms while also strengthening the bond between mother and child.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Baby swimming — Participants in the treatment group will be contacted by a researcher and invited to an introductory meeting at the swimming facility, where they will receive information about the baby swimming course from the instructor. The course will take place twice a week for five weeks, totaling 10 sessions of 30 minutes each. During the sessions, mothers will be encouraged to engage in physical contact, maintain eye contact, and respond to their baby's signals. The course will also include water safety exercises.

Primary Outcomes

  • Depressive symptoms (Seven months follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Uppsala University
Contact Information
Study Contact:
Alkistis Skalkidou, PhD, MD
+46 6110000
alkistis.skalkidou@kbh.uu.se
Sara Sylvén, PhD, MD
+46706110451
sara.sylven@neuro.uu.se
Interventions
  • Behavioral: Baby swimming — Participants in the treatment group will be contacted by a researcher and invited to an introductory meeting at the swimming facility, where they will receive information about the baby swimming course from the instructor. The course will take place twice a week for five weeks, totaling 10 sessions of 30 minutes each. During the sessions, mothers will be encouraged to engage in physical contact, maintain eye contact, and respond to their baby's signals. The course will also include water safety exercises.
Study Locations (1 sites)
Uppsala University, Uppsala, Sweden
Eligibility Criteria
Inclusion Criteria: Women who have * given birth at full term * are 18 years or older * have a baby aged 3-7 months at the time of inclusion * exhibit depressive symptoms according to the EPDS scale. Exclusion Criteria: * Multiple pregnancy (twins, triplets) * Known psychotic disorder or bipolar disorder * Inability to communicate adequately in Swedish or English, or inability to read and complete digital questionnaires in Swedish or English.
Conditions Postpartum Depression
Phase NA
Enrollment 160
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the use of an automated process in the electronic health record (EHR) that will help providers to detect patients at risk of developing postpartum depression (PPD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Clinical Decision Support Tool — The CDS in and AI algorithm that will alert clinicians only if patients have high risk of developing PPD, and provide clinicians with risk score, risk factors, and anticipatory actions with an order set to assist with ordering. Clinicians will make the ultimate clinical judgement after receiving CDS aid, including taking no actions towards PPD prevention. Clinicians will manage patients per usual care, including initiating PPD prevention such as conducting referrals to nutrition and behavioral health, suggest educational readings through patient portals, or no actions. Clinicians in the intervention arm will refer patients based on the CDS.

Primary Outcomes

  • Acceptability as measured by Unified Theory of Technology Acceptance Theory (UTAUT). (One month after initiation of tool use and three months after use.)
  • Appropriateness as measured by Appropriateness Measure (IAM). (One month after initiation of tool use and three months after use.)
  • Feasibility as measured by Feasibility of Intervention Measure (FIM). (One month after initiation of tool use and three months after use.)
  • Mental Health service utilization as measured by number of mental health visits (one month and three month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Principal Investigators:
  • Yiye Zhang, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Rochelle Joly, MD
646-962-4222
roj9069@med.cornell.edu
Tracy Grossman, MD
trg2005@med.cornell.edu
Center for Community Health: 515 6th street (3rd floor)
Jessica Miller
718-499-2273
Center for Community Health: 515 6th street (3rd floor)
Interventions
  • Other: Clinical Decision Support Tool — The CDS in and AI algorithm that will alert clinicians only if patients have high risk of developing PPD, and provide clinicians with risk score, risk factors, and anticipatory actions with an order set to assist with ordering. Clinicians will make the ultimate clinical judgement after receiving CDS aid, including taking no actions towards PPD prevention. Clinicians will manage patients per usual care, including initiating PPD prevention such as conducting referrals to nutrition and behavioral health, suggest educational readings through patient portals, or no actions. Clinicians in the intervention arm will refer patients based on the CDS.
Study Locations (4 sites)
Center for Community Health: 515 6th street (3rd floor), Brooklyn, New York 11215 United States
Ob GYN Lower Manhattan 156 William street, New York City, New York, New York 10038 United States
Weill Cornell Medicine OBGYN practice 72 street, New York, New York 10065 United States
Weill Cornell Medicine- Women's Health practice 505 East 70th street, New York City, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * 18 years or older * being seen at one of participating clinics * pregnancy at 20 week gestation or more Exclusion Criteria: * Does not speak inclusion * does not have internet access Clinician eligibility: * If they manage patients in the three clinics as a board-certified OBGYN clinician. * No exclusion criteria apply for clinician based on their knowledge and experience in treating PPD
Conditions Adolescent Asthma
Phase PHASE2
Enrollment 252
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RSS0343 Tabella — RSS0343 tablets, oral;

Primary Outcomes

  • The number of occurrences of AEs (Day 1 to Day56)
  • the frequency of occurrence of AEs (Day 1 to Day56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-22
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Contact Information
Study Contact:
Zi Lin
+0518-81220121
zi.lin.zl30@hengrui.com
Weijie Guan
First Affiliated Hospital of Guangzhou Medical University
Interventions
  • Drug: RSS0343 Tabella — RSS0343 tablets, oral;
Study Locations (1 sites)
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510140 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years old (including boundary values), male and female. 2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB. 4. The expected survival is greater than 12 months. 5. Informed consent was signed before the trial. 6. Potentially fertile subjects voluntarily take appropriate contraceptive measures. Exclusion Criteria: 1. Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened. 2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc. 3. Have psoriasis or lichen planus. 4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. Have chlorine acne, large common warts, or keratodermatitis. 6. Has diabetic foot. 7. Have periodontal disease, oral infection, or loose teeth. 8. History of malignant tumor within 5 years prior to screening. 9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. Researchers consider any other unstable clinical disease. 11. Oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. Immunosuppressants were administered 4 weeks before the first dose. 13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. Received live attenuated vaccine within 30 days prior to initial administration. 15. Participated in clinical trials of any medical device within 3 months prior to screening. 16. Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection. 17. Drug abusers. 18. Current smoker or former smoker for less than 3 months. 19. Suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure. 20. Pregnant or lactating women. 21. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 22. The researchers determined that there were other circumstances that were not suitable for participation in this study.
Conditions Advanced Breast Cancer
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: PD-1 / PD-L1 monoclonal antibody — Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.

Primary Outcomes

  • Progression-Free Survival (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-24
Completion: 2028-09-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma
010-87788120
drmafei@126.com
Fei Ma M.D
01087788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: PD-1 / PD-L1 monoclonal antibody — Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: Subjects are eligible for inclusion in the study only if all the following criteria apply: 1. Men or women who are 18 years of age or older on the day of signing the informed consent; 2. Patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology; 3. Patients who, after MDT discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy; 4. Patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy; 5. Patients with a traceable medical history during treatment; 6. Subjects who are able to sign an informed consent to participate in the study. Exclusion Criteria: 1. Subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of CNS involvement, they should be excluded by a cranial MRI scan; 2. Have not signed the informed consent form; 3. Pregnant or lactating women; 4. Other conditions deemed unsuitable for inclusion in the study by the investigator.
Conditions Type 2 Diabetes, Motivation, Self-manage...
Phase NA
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Objective: The aim of this study was to determine the effects of diabetes education given to individuals with diabetes using motivational interviewing technique based on the health promotion model on diabetes self-management and cyberchondria severity. Materials and Method: The population of the study consisted of 1000 individuals. The sample consisted of 64 individuals, 32 experimental and 32 control, who met the research criteria. The research will be conducted between 15.02.2025-15.03.2025 in Van Regional Training and Research Hospital Diabetes outpatient clinic. Data in the research; Descriptive Information Form, Diabetes Self-Management Scale (DMS), Cyberchondria Severity Scale-Short Form (CSS-SF) scales will be applied. Research experiment Motivational interviewing intervention based on the health belief model will be conducted once a week for 1 month. At the end of 1 month, both scales will be administered again to individuals in both experimental and control groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Experimental Group — Individuals will receive diabetes education with motivational interviewing technique based on health belief model.

Primary Outcomes

  • Cyberchondria Severity Scale-Short Form (CSS-SF) (one months)
  • Diabetes Self-Management Perception Scale (DSMAS) (one month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-15
Completion: 2025-08-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ataturk University
Contact Information
Study Contact:
Gülşen ALTUNTAŞ ÇALIM, PhD student
+905535383055
gulsenaltuntas13@hotmail.com
Gülşen ALTUNTAŞ ÇALIM, PhD student
05535383055
gulsenaltuntas13@hotmail.com
Van Regional Training and Research Hospital Diabetes Polyclinic
Gülşen ALTUNTAŞ ÇALIM, PhD student
Van Regional Training and Research Hospital Diabetes Polyclinic
Interventions
  • Other: Experimental Group — Individuals will receive diabetes education with motivational interviewing technique based on health belief model.
Study Locations (1 sites)
Van Regional Training and Research Hospital Diabetes Polyclinic, Van, Van 65100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Having diabetes for at least 6 months * Being over 18 years old * To have sufficient communication skills to answer verbal and written questions and fulfill instructions * Being literate * No physical, cognitive or mental impairment in answering the questions * Willingness to participate in research. Exclusion Criteria: * Being under 18 years of age * Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process * The emergence of any health problem that prevents the person from continuing the research * Do not leave the study voluntarily.
Conditions Asthma in Children, Chronic Diseases in ...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A randomized controlled trial with parent-child pairs of children with persistent or uncontrolled asthma. An intervention group (n=40 parent-child pairs) will receive the mobile health (mHealth) app and digital sensors with enhanced support from a population health manager role, hereinafter referred to as an asthma coordinator, to provide remote patient monitoring (RPM). A comparison group (n=40 parent-child pairs) will receive the mHealth app and sensors without RPM support to silently collect inhaler use information without mHealth app features. The focus of this project is to evaluate the feasibility and acceptability of delivering a digital intervention for pediatric asthma with RPM in the outpatient setting.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digital Asthma Intervention — The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
  • Behavioral: Comparison Group — Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.

Primary Outcomes

  • Study Feasibility (Baseline, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-14
Completion: 2027-01
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Kristin Kan, MD
3122276110
kkan@luriechildrens.org
Olivia Orr
oorr@luriechildrens.org
Interventions
  • Behavioral: Digital Asthma Intervention — The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
  • Behavioral: Comparison Group — Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.
Study Locations (1 sites)
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion into the study will not depend on sex, ethnicity, or race. We will monitor enrollment to ensure a diversity of sex and race/ethnicity are represented. PARENT-CHILD PAIR INCLUSION CRITERIA 1. Caregivers must be at least 18 years old (defined as parent or legal guardian) 2. The child (patient) has a diagnosis of asthma associated with a clinic visit in the electronic health record 3. The child is between the ages of 4-17 years old at the time of recruitment 1. The study is interested in the self-management of asthma by caregivers, whom are still primarily responsible for their child's chronic disease management. 2. Children younger than 4 years old will not be included in this study as the diagnosis of asthma is typically difficult to confirm in younger ages. 4. The child is prescribed inhaled corticosteroid or corticosteroid/long-acting beta agonist combination for daily use. The patient can have an inhaled corticosteroid/long-acting beta agonist for both daily preventive and rescue use, as in Single Maintenance and Reliever Therapy (SMART). 5. Persistent or un controlled asthma based on NHLBI guidelines40; Any 1 of the following: 1. In past month, \>2 days per week with asthma symptoms 2. \>2 days per week with rescue medication use 3. \>2 days per month with nighttime awakenings (for children who are not taking a controller asthma medication) OR \>2 days per month with nighttime awakenings (for children who are currently taking a controller asthma medication) 4. \>2 asthma episodes during the past year that required systemic corticosteroids 6. The child is a patient in Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH PARENT-CHILD PAIR EXCLUSION CRITERIA 1. The caregiver has a smartphone that is not compatible with the Hailie® app. 2. The patient is prescribed a controller (preventive) or rescue inhaler medication to which the Hailie electronic sensor cannot affix. 3. The caregiver is unable to speak and understand English. a. With this trial, the intent is to first establish feasibility and broaden to different languages in future. 4. The child has clinically significant, comorbid diagnoses, such as cystic fibrosis, cyanotic heart disease, or bronchopulmonary dysplasia, that could interact with their assessment of asthma-related measures. 5. The family has active Department of Child and Family Services (DCFS) involvement 6. The participant is enrolled in another asthma intervention study at the time of enrollment to this study. 7. Child or sibling living in the same home was previously enrolled in this study. 8. Consent is not obtained from the parent/guardian. 9. Parent/guardian does not pass the test of understanding at study enrollment. HEALTH CARE PROVIDER INCLUSION CRITERIA (IMPLEMENTATION OUTCOMES) 1. Participant is an employee of LCH system 2. Works at or supports the operations of Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH 3. Able to provide informed consent HEALTH CARE PROVIDER EXCLUSION CRITERIA (IMPLEMENTATION OUTCOMES) 1\. Participant departs LCH and is no longer an active employee at the time of assessment